Press Release: Medical Resorts International
December 6, 2000
TORONTO, Ontario -- Medical Resorts International, Inc. (Pink Sheets: MRINF) has entered into a 5 year contract
with Aladdin Pharmaceutical to conduct clinical studies related to a new scientific breakthrough treatment for
HIV and AIDS at its Hotel de Health medical facility located on Anguilla.
The purpose of the testing is to validate and to substantiate previous test results obtained as well as increase
the amount of clinical data available for analysis.
Previous Human clinical studies of the HIV/AIDS treatment have demonstrated a significant improvement in the health
care status of 60 out of 70 individuals within a 90 to 120 day time frame.
The Medical and Scientific Advisory Committee will also assist in the development and implementation of testing
protocols to be compliant with FDA standards. ``We anticipate entering into the first clinical phase of testing
for FDA approval in the United States within the next 30 days,'' Robert Talbot, President of Medical Resorts International.
Safe Harbor Act Notice: This release may contain forward-looking statements that involve risks and uncertainties,
including, without limitation, acceptance of the company's products, increased levels of competition, product and
technological changes, the company's dependence upon financing and third-party suppliers, and other risks detailed
from time to time in the company's federal filings, annual report, offering memorandum, or prospectus. Specifications
are subject to change without notice.
SOURCE: Medical Resorts International